RxDoctor Payments Data

Kevin Doyle, MD

Otolaryngology · Raleigh, NCNPI 1972573608

Payments from drug & device makers

$3,701in general payments, 2019–2025

Across 52 payments — averaging $71.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Verathon Inc.$2K
  • Acclarent, Inc$255
  • Alk-abello, Inc$239
  • Regeneron Healthcare Solutions, Inc.$217
  • Aerin Medical Inc.$209
  • GSK$207
  • plus $775 from 13 others

What the payments were for

  • Consulting fees$1,80049%
  • Food & beverage$1,86750%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,701 in reported general payments places this provider in the 80th percentile of 362 otolaryngology providers in North Carolina.

See all otolaryngology providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,578
Medicare patients
461
Services billed
1,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide142$5,009
Epinephrine17$3,041
Fluticasone Propionate103$2,074
Azelastine Hcl61$1,920
Wixela InhubFluticasone Propion/Salmeterol17$1,677
Ofloxacin30$1,504
Levocetirizine Dihydrochloride45$824
Montelukast Sodium41$320
Methylprednisolone55$301
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$278
Fluocinonide15$146
Prednisone40$137
Alprazolam12$108
Mupirocin18$96
Ondansetron OdtOndansetron18$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$26$3,04117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 362 otolaryngology providers in North Carolina.

Other otolaryngology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →